

Embargoed: 0700hrs, 3 May 2007

Akers Biosciences, Inc

('Akers' or the 'Company')

Receipt of United States Military Contract

Akers Biosciences, Inc. (LSE.AKR) is delighted to announce that it has received, through `Bout Time Marketing, LLC, whose assets are entirely owned by the Company, an order from a branch of the United States Military, for its Legal Limit and BreathScan product lines. The contract value of this first Military order in 2007 is approximately \$500,000.

The Company has previously stated that it had expected significant orders from several departments of the United States Government as a result of its efforts to increase safety awareness. The Legal Limit and BreathScan products are considered the industry gold standard. Today's contract represents the continuance of a program that begun in late 2006 and the Company expects other branches of the Military to follow suit, such as the Army and Navy who have already placed the products and program in their 'Best Practices' Safety Programs.

Dr. Ray Akers, CEO of Akers Biosciences, Inc. said, 'We are very pleased to be able to assist the US Military in the protection and safety of its troops as our products have been proven to produce very positive results. These products and programs have not only wide applications within the United States Government, but can also address similar safety issues in civilian sectors including transportation, education, maritime and privately sponsored safety programs.'

Enquiries:

Akers Biosciences, Inc.

Dr. Raymond Akers, Chief Executive Officer or  
Thomas A. Nicolette, President

Tel. 001 856 848 8698 / 020 7917 9476

Hansard Group

Ben Simons

Tel. 020 7245 1100

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring rapid healthcare information directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare

companies and high volume medical products distributors to maximize product offerings and be a major worldwide provider of rapid diagnostics. Additional information on the Company and its products can be found at [www.akersbiosciences.com](http://www.akersbiosciences.com).

END